Goldman Sachs Upgrades Merck On Cancer, HIV, COVID-19 Pipeline
Goldman Sachs Upgrades Merck On Cancer, HIV, COVID-19 Pipeline
Merck & Co., Inc’s (NYSE: MRK) internal pipeline seems underappreciated by the market, and the loss of exclusivity of its cancer immunology drug Keytruda appears priced in, according to Goldman Sachs.
The Merck Analyst: Terence Flynn upgraded Merck from Neutral to Buy and raised the price target from $91 to $105.
The Merck Thesis: The market seems to be underappreciating a potential opportunity of between $13 billion and $18 billion in pipeline assets, Flynn said in the Monday upgrade note. (See his track record here.)
Merck has developed several earlier stage cancer assets that can be used in combination with Keytruda or in patients who do not respond to Keytruda, the analyst said, adding that Phase I and II data may emerge at the ESMO conference in September and over the next year.
Phase II and III trials are underway for Islatravir for both treatment and prevention of HIV. Phase II prevention data is expected later this year, Flynn said. Merck may partner with another longer-acting drug “to create a long-acting injectable formulation that could represent the next innovation in the HIV market,” the analyst said.
The company has a COVID-19 treatment in Phase II and vaccine candidates that could enter clinical trials in the second half of 2020, according to Goldman Sachs.
MRK Price Action: Shares of Merck were up 4.27% at $83.67 at last check Monday.
Related Links:
10 Biggest Price Target Changes For Monday
Four-For-Four: Perfect Day At The Plate For FAANGs As Apple, Amazon, Facebook Up Big Early Latest Ratings for MRK
View More Analyst Ratings for MRK
View the Latest Analyst Ratings
Merck & Co., Inc’s (NYSE: MRK) internal pipeline seems underappreciated by the market, and the loss of exclusivity of its cancer immunology drug Keytruda appears priced in, according to Goldman Sachs.
The Merck Analyst: Terence Flynn upgraded Merck from Neutral to Buy and raised the price target from $91 to $105.
默克分析師： 特倫斯·弗林將默克從中性升級為買入，並將目標價格從 91 美元提高到 105 美元。
The Merck Thesis: The market seems to be underappreciating a potential opportunity of between $13 billion and $18 billion in pipeline assets, Flynn said in the Monday upgrade note. (See his track record here.)
默克論文： Flynn 在周一的升級說明中表示，市場似乎沒有估值 130 億美元至 180 億美元的管道資產的潛在機會。（在這裡查看他的往績記錄。）
Merck has developed several earlier stage cancer assets that can be used in combination with Keytruda or in patients who do not respond to Keytruda, the analyst said, adding that Phase I and II data may emerge at the ESMO conference in September and over the next year.
分析師表示，默克已經開發了幾種較早期的癌症資產，可與 Keytruda 結合使用，或者用於對 Keytruda 沒有反應的患者，並補充說，在 9 月和明年的 ESMO 會議上可能會出現 I 期和 II 期數據。
Phase II and III trials are underway for Islatravir for both treatment and prevention of HIV. Phase II prevention data is expected later this year, Flynn said. Merck may partner with another longer-acting drug “to create a long-acting injectable formulation that could represent the next innovation in the HIV market,” the analyst said.
伊拉韋的治療和預防艾滋病毒正在進行 II 和 III 期試驗。Flynn 表示，預計今年晚些時候將有二期預防數據。分析師說，默克可能與另一種長效藥物合作，「創造一種長效注射配方，可以代表艾滋病毒市場的下一個創新。」
The company has a COVID-19 treatment in Phase II and vaccine candidates that could enter clinical trials in the second half of 2020, according to Goldman Sachs.
據高盛表示，該公司在第二期接受 COVID-19 治療，並在 2020 年下半年進入臨床試驗的候選疫苗。
MRK Price Action: Shares of Merck were up 4.27% at $83.67 at last check Monday.
MRK 價格行動： 默克在上次檢查週一上漲 4.27％，至 83.67 美元。
Related Links:
相關連結：
10 Biggest Price Target Changes For Monday
週一 10 最大的目標價格變化
Four-For-Four: Perfect Day At The Plate For FAANGs As Apple, Amazon, Facebook Up Big Early Latest Ratings for MRK
View More Analyst Ratings for MRK
查看更多 MRK 的分析師評級
View the Latest Analyst Ratings
查看最新的分析師評級
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧